# A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

> **NCT06869551** · PHASE3 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 60 (estimated)

## Conditions studied

- Juvenile Psoriatic Arthritis

## Interventions

- **DRUG:** Deucravacitinib
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06869551
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-13
- **Primary completion:** 2030-03-06
- **Final completion:** 2031-03-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06869551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06869551, "A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06869551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*